Reddys], we have enough demand for the product from other customers, including for Canada, and our capacities are fully committed, OneSource Specialty Pharma said in a regulatory filing
In a statement, Dave Moore, executive vice president of U.S
In addition, baseline chronic conditions with a prevalence of at least 2% in the overall multimorbid population were used to identify homogeneous groups of participants with multimorbidity (that is, two or more diseases), sharing similar combinations of chronic diseases (Supplementary Table 8) 6,62
These prices place brand-name GLP-1 medications out of reach for most people without insurance coverage or manufacturer copay assistance programs
Several treatment options are available from diet and lifestyle changes to supplements, prescription medications, and more